Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURE: Sunitinib Alternating with Regorafenib in GIST
NCT02164240Phase 1Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jul 2014
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sunitinib and regorafenib in gastrointestinal stromal tumor (GIST), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Number of Participants With Serious and Non-Serious Adverse Events. Started Jul 2014; status: completed.
02
Drugs
sunitinibregorafenib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT02164240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02164240.